KEYNOTE-189 and KEYNOTE-407 are two clinical trials that have produced promising results (7) (8), have discovered that combining PD-1/PD-L1 inhibitors with chemotherapy significantly improved progression-free survival and overall survival in patients with advanced non-small cell lung cancer who were driver-negative, lowering the risk of disease progression and death. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.